Skip to content
No results
  • Home
  • News
  • Press Releases
  • Business
  • Technology
  • Research
  • Regulatory
  • Events and Conferences
  • About Us
  • Contact Us
  • About Us
  • Contact Us
The Pharma Data
  • News
  • Press Releases
  • Business
  • Technology
  • Research
  • Regulatory
  • Events and Conferences
The Pharma Data
  • Press ReleasesResearch

C2N Diagnostics Expands Alzheimer’s Blood Test Portfolio for Researchers

  • The Pharma Data
  • July 16, 2025

C2N Diagnostics Unveils Two Groundbreaking Blood Tests to Advance Alzheimer’s Research and Precision Diagnostics C2N Diagnostics, LLC, a trailblazer in brain health diagnostics, has announced the launch of two innovative…

Read MoreC2N Diagnostics Expands Alzheimer’s Blood Test Portfolio for Researchers
  • Research

Enveric’s EB-003 Shows Promise in Preclinical PTSD Model

  • The Pharma Data
  • July 16, 2025

Enveric Biosciences’ Lead Candidate EB-003 Shows Promising Preclinical Efficacy in PTSD Model, Signaling a Potential Breakthrough in Neuroplasticity-Based Psychiatric Treatment Enveric Biosciences (NASDAQ: ENVB), a pioneering biotechnology company advancing a…

Read MoreEnveric’s EB-003 Shows Promise in Preclinical PTSD Model
  • ResearchTechnology

EyeDura’s Sustained-Release Eye Drop Technology Earns Dual Industry Accolades

  • The Pharma Data
  • July 16, 2025

EyeDura Therapeutics Wins Top Industry Honors as Its Sustained-Release Eye Drop Technology Gains Momentum in Ophthalmology Innovation EyeDura Therapeutics Inc., a trailblazing developer of preservative-free, sustained-release ophthalmic therapies, has garnered…

Read MoreEyeDura’s Sustained-Release Eye Drop Technology Earns Dual Industry Accolades
  • Regulatory

Vistagen Recognized for Exemplary Workplace Culture and Leadership in Mental Health

  • The Pharma Data
  • July 16, 2025

Vistagen Earns Dual Honors for Mental Health Advocacy and Exceptional Workplace Culture in 2025 Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company revolutionizing neuroscience with its novel nose-to-brain neurocircuitry platform,…

Read MoreVistagen Recognized for Exemplary Workplace Culture and Leadership in Mental Health
  • Press Releases

ZYUS Life Sciences Appoints CMO to Lead Phase 2 Cancer Pain Trial

  • The Pharma Data
  • July 16, 2025

ZYUS Life Sciences Appoints Dr. Julie Stakiw as Chief Medical Officer to Advance Phase 2 Oncology Pain Program and Strengthen Clinical Development Leadership In a pivotal step toward accelerating its…

Read MoreZYUS Life Sciences Appoints CMO to Lead Phase 2 Cancer Pain Trial
  • News

JCR and Acumen Partner to Develop Alzheimer’s Therapy Using J-Brain Cargo®

  • The Pharma Data
  • July 16, 2025

JCR Pharmaceuticals and Acumen Pharmaceuticals Forge Strategic Partnership to Develop a Blood-Brain Barrier-Penetrating Alzheimer’s Therapy Using J-Brain Cargo® Platform JCR Pharmaceuticals Co., Ltd. (TSE: 4552), a Japan-based global specialty biopharmaceutical…

Read MoreJCR and Acumen Partner to Develop Alzheimer’s Therapy Using J-Brain Cargo®
  • Business

PCI Pharma Services Enters New Growth Phase with Strategic Investment

  • The Pharma Data
  • July 16, 2025

PCI Pharma Services Embarks on Next Growth Phase with Strategic Investment from Bain Capital, Kohlberg, and Mubadala PCI Pharma Services (PCI), a globally recognized contract development and manufacturing organization (CDMO)…

Read MorePCI Pharma Services Enters New Growth Phase with Strategic Investment
  • Regulatory

FDA Grants De Novo Nod to Reflow’s Spur Stent System

  • The Pharma Data
  • July 15, 2025

Reflow Medical Receives FDA De Novo Clearance for Spur Stent System, Marking a Breakthrough in Treatment of Below-the-Knee Peripheral Arterial Disease Reflow Medical, Inc., a pioneering company in the development…

Read MoreFDA Grants De Novo Nod to Reflow’s Spur Stent System
  • Business

CEL-SCI Closes $5.7M At-The-Market Stock Offering Under NYSE American Guidelines

  • The Pharma Data
  • July 15, 2025

CEL-SCI Secures $5.7 Million in At-the-Market Equity Offering to Advance Cancer Immunotherapy Program CEL-SCI Corporation (NYSE American: CVM), a clinical-stage biotechnology company dedicated to developing cancer immunotherapy treatments, has successfully…

Read MoreCEL-SCI Closes $5.7M At-The-Market Stock Offering Under NYSE American Guidelines
  • Regulatory

Samsung Bioepis Whitepaper Calls for Policy Reforms to Boost Biosimilar Access in Europe

  • The Pharma Data
  • July 15, 2025

Samsung Bioepis Unveils European Policy Whitepaper to Bridge Gaps Hindering Biosimilar Access and Market Sustainability Samsung Bioepis Co., Ltd. has published a comprehensive whitepaper titled “Solving the Biosimilar Void in…

Read MoreSamsung Bioepis Whitepaper Calls for Policy Reforms to Boost Biosimilar Access in Europe
  • News

New Guideline Expands Access to Advanced Liver Ultrasound, Experts Say

  • The Pharma Data
  • July 15, 2025

New Guidelines Expand Access to Advanced Liver Imaging and Transplant Evaluations Using Contrast-Enhanced Ultrasound A new policy change is being hailed by medical experts as a transformative advancement in the…

Read MoreNew Guideline Expands Access to Advanced Liver Ultrasound, Experts Say
  • Press Releases

HistoSonics Secures Coverage for Liver Tumor Therapy in 7M Highmark Members

  • The Pharma Data
  • July 15, 2025

HistoSonics Expands Access to Groundbreaking Non-Invasive Liver Tumor Treatment as Highmark Covers Histotripsy for 7 Million Members In a pivotal development for patients battling liver tumors, HistoSonics, the medical technology…

Read MoreHistoSonics Secures Coverage for Liver Tumor Therapy in 7M Highmark Members
PrevNext

About

The Pharma Data is an Information-Centric Website focused mainly on the Pharmaceutical Industry Online It is a B2B Platform mainly focused on the latest Pharmaceutical News, Press releases, Industry-related updates, Events, and Conferences. With The Pharma Data, you can get all the information that happening in the Pharmaceutical industry.

Advertise With Us: marketing@thepharmadata.com

Latest Posts

  • EmeraNova™ Strengthens Innovation Leadership with Launch of New Accelerator ProgramNovember 5, 2026
  • Global Healthy Living Foundation Highlights Advances in Myositis and Polymyalgia Rheumatica Research at ACR Convergence 2026November 5, 2026
  • Polaris Rx Chosen by Bristol Myers Squibb to Distribute ZENBEXUS™, the First FDA-Approved CELMoD Treatment for Multiple MyelomaNovember 5, 2026
  • About Us
  • Disclaimer
  • Privacy Policy
  • Terms and Conditions
  • Contact Us

Copyright © 2026 | The Pharma Data | Marnet Technologies Pvt Ltd | All Rights Reserved.